Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974062 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CYP1A2CYP2C19PPARG | |
| SCHEMBL3967838 | 0.96 | PPARG (0.41) | ALDH1A1CYP1A2CYP2C19PPARG | |
| SCHEMBL3967834 | 0.96 | PPARG (0.41) | ALDH1A1CYP1A2CYP2C19PPARG | |
| SCHEMBL3961997 | 0.90 | ALDH1A1 (0.38) | ALDH1A1CYP1A2CYP2C19PPARG | |
| SCHEMBL3961991 | 0.90 | ALDH1A1 (0.38) | ALDH1A1CYP1A2CYP2C19PPARG | |
| SCHEMBL16548381 | 0.86 | ALDH1A1 (0.42) | ALDH1A1CYP1A2CYP2C19PPARG | |
| SCHEMBL1027980 | 0.82 | ALDH1A1 (0.49) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3969245 | 0.82 | ALDH1A1 (0.49) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL1027979 | 0.82 | ALDH1A1 (0.49) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3968568 | 0.76 | CHRNA7 (0.47) | ALDH1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572809-B2 | Isoquinoline aminopyrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1966190-A1 | ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| US-20070179151-A1 | Isoquinoline aminopyrazole derivatives | F. HOFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | US | disclosed |
| WO-2007071348-A1 | ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179151-A1 | Isoquinoline aminopyrazole derivatives | CYP3A5, CYP3A43, CYP3A4 | ALDH1A1 198/4885CYP1A2 9/4885CYP2C19 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.